Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:EQ NYSE:NKGN NYSE:OGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.56+8.0%$2.03$0.95▼$2.87$21.27M0.13185,119 shs412,533 shsEQEquillium$0.39-5.6%$0.36$0.27▼$1.50$13.97M1.86470,371 shs294,220 shsNKGNNKGen Biotech$0.21-12.5%$0.29$0.10▼$1.36$9.44M1.261.41 million shs558 shsOGENOragenics$1.38+4.5%$3.75$1.30▼$75.60$1.14M0.95207,654 shs166,565 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma0.00%+10.23%+18.50%+125.71%-15.05%EQEquillium-0.24%+12.96%+26.67%-10.95%-52.40%NKGNNKGen Biotech0.00%-20.29%-4.00%+51.32%-79.83%OGENOragenics-2.22%-6.38%-63.84%-76.47%-95.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYTUAytu BioPharma3.7726 of 5 stars3.54.00.03.41.10.00.6EQEquillium2.2163 of 5 stars3.24.00.00.00.61.70.6NKGNNKGen Biotech0.7006 of 5 stars0.03.00.00.01.72.50.0OGENOragenics0.0697 of 5 stars0.02.00.00.01.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 3.00Buy$10.00290.63% UpsideEQEquillium 2.33Hold$3.00667.26% UpsideNKGNNKGen Biotech 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OGEN, AYTU, NKGN, and EQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81M0.28N/AN/A$4.64 per share0.55EQEquillium$41.10M0.34N/AN/A$0.54 per share0.72NKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.720.00∞N/A2.37%3.51%0.91%9/24/2025 (Estimated)EQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)NKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/AOGENOragenics-$20.66M-$33.63N/A∞N/AN/A-2,087.95%-486.56%N/ALatest OGEN, AYTU, NKGN, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.030.87EQEquilliumN/A2.702.70NKGNNKGen BiotechN/A0.020.02OGENOragenicsN/A1.931.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%EQEquillium27.05%NKGNNKGen Biotech76.17%OGENOragenics18.71%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%EQEquillium30.30%NKGNNKGen Biotech10.36%OGENOragenics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableEQEquillium4035.72 million24.90 millionNot OptionableNKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionableOGENOragenics5823,00010.98 millionN/AOGEN, AYTU, NKGN, and EQ HeadlinesRecent News About These CompaniesOragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical DevelopmentJuly 16, 2025 | globenewswire.comOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Seeking AlphaJuly 3, 2025 | seekingalpha.comOragenics stock tumbles after announcing $20 million preferred stock offeringJuly 2, 2025 | investing.comOragenics Completes Approximately $16.5 Million OfferingJuly 2, 2025 | globenewswire.comSarasota biotech company announces $20M public offeringJuly 2, 2025 | businessobserverfl.comBOragenics shares plunge following announcement of $20 million preferred stock saleJuly 1, 2025 | msn.comOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and WarrantsJuly 1, 2025 | globenewswire.comOragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 11, 2025 | nasdaq.comOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 10, 2025 | finance.yahoo.comOragenics Inc.June 4, 2025 | wsj.comOragenics, Inc. Announces One-for-Thirty Reverse Stock SplitMay 29, 2025 | finance.yahoo.comOragenics Hosts Neurotrauma Medicine Webinar PresentationMay 20, 2025 | tipranks.comOragenics gains Australia’s nod for concussion therapy trialMay 15, 2025 | uk.investing.comOragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion TreatmentMay 14, 2025 | nasdaq.comOragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in AustraliaMay 13, 2025 | globenewswire.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion ...May 12, 2025 | gurufocus.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic VisionMay 12, 2025 | globenewswire.comOragenics Appoints Janet Huffman as CEO and CFOMay 2, 2025 | tipranks.comOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury ConferenceApril 23, 2025 | manilatimes.netMOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN ...April 23, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug Power3 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025View 3 Bullish Biotech Stocks With Explosive Growth Trends3 Hot Trades for Insiders, But Are They Good Buys for Investors?By Thomas Hughes | June 24, 2025View 3 Hot Trades for Insiders, But Are They Good Buys for Investors?New Catalyst Sends Joby Stock to 52-Week HighsBy Jeffrey Neal Johnson | July 15, 2025View New Catalyst Sends Joby Stock to 52-Week HighsOGEN, AYTU, NKGN, and EQ Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.56 +0.19 (+8.02%) Closing price 04:00 PM EasternExtended Trading$2.56 0.00 (-0.20%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Equillium NASDAQ:EQ$0.39 -0.02 (-5.58%) Closing price 04:00 PM EasternExtended Trading$0.41 +0.02 (+4.09%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.NKGen Biotech NYSE:NKGN$0.21 -0.03 (-12.50%) As of 02:58 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Oragenics NYSE:OGEN$1.38 +0.06 (+4.55%) Closing price 04:00 PM EasternExtended Trading$1.41 +0.03 (+2.17%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Block Levels Up: What S&P 500 Inclusion Means for Investors Steel Dynamics Stock Steady on Long-Term Prospects Amazon Stock Rally Hits New Highs: Buy Into Earnings? A Bullish Storm Is Brewing for High-Yield Verizon’s Share Price Forget the Hype—TSMC Is the AI Stock That Actually Delivers Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.